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Objectives.The aim of this study is to assess the feasibility and clinical outcome of transcatheter aortic valve replacement (TAVR)
using aortic valve predilatation (AVPD) with a small, nonocclusive balloon. Background. Balloon aortic valvuloplasty (BAV) under
rapid pacing is generally performed in TAVR to ensure the passage and sufficient deployment of the prosthesis in the stenotic AV.
BAV may cause serious complications, such as left ventricular stunning or cerebrovascular embolism. Methods. A cohort of 50
consecutive patients with severe aortic stenosis underwent transfemoral TAVR with the Edwards Sapien 3-heart valve. All patients
underwent AVPD with a small, nonocclusive balloon (12 × 60 or 14 × 60mm) without rapid pacing. Procedural data and clinical
outcomes were analyzed. Results.Themean age of the cohort was 81±6 years and the mean logistic EuroSCORE (European System
for Cardiac Operative Risk Evaluation) was 13 ± 9. Crossing the AV and prosthesis implantation was successful in all cases. The
postprocedural mean AV gradient was 12 ± 5mmHg. There were no cases of aortic regurgitation ≥ grade 2. No periprocedural
stroke occurred. One patient (2%) with chronic atrial fibrillation displayed a transient Wernicke aphasia occurring more than 24
hours after TAVR. Mortality was 0% at 30 days after procedure. Conclusion. In TAVR, AVPD with a small, nonocclusive balloon
can be safely performed. By avoiding rapid pacing, this technique may be a valid alternative to traditional BAV.Whether or not the
use of APVD without rapid pacing translates into less periprocedural complications needs to be assessed in future studies.
1. Introduction
Transfemoral transcatheter aortic valve replacement (TAVR)
has evolved into the standard of care for patients with
severe, symptomatic aortic stenosis (AS) at intermediate,
inoperable, or high surgical risk [1]. As device caliber and
technological improvements continue to garner increasing
attention, some cornerstones of transfemoral implantation
techniques remain unchanged. Such principles are rapid
pacing and balloon aortic valvuloplasty (BAV) prior to
valve implantation [2, 3]. However, the impact of transient
ventricular stunning during rapid pacing is unclear, and BAV
during TAVR may contribute to cerebral microembolization
of calcified debris from the aortic valve [4, 5]. The aim of
our current study is to assess the safety and feasibility of
AVPD prior to TAVR using a small and nonocclusive balloon
without the use of rapid ventricular pacing.
2. Methods
2.1. Patient Selection and Preparation. From February 2014
until June 2014, we prospectively evaluated and treated 50
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Figure 1: CT-imaging of aortic valves with different degree of calcification. Schematic effect of AVPD with a small, “nonocclusive” balloon.
consecutive patients with severe, symptomatic AS using
AVPD prior to implantation of the Sapien 3 (Edwards Life-
sciences, Irvine, CA, USA) transcatheter heart valve (THV).
All patients undergoing TAVR were evaluated with a
transthoracic echo (TTE), coronary angiogram, and an
ECG gated 384-slice, multidetector computed tomography
angiogram (CTA) of the heart and thoracic, abdominal and
bilateral lower extremity vasculature. At the time of the proce-
dure, an aortic root and selective iliofemoral angiogramswere
performed. The procedure was performed under conscious
sedation in majority of the cases. A TTE was obtained on all
patients on postprocedure day one to assess the aortic valve
anatomy and function including obtaining hemodynamic
measurements.
2.2. TAVR Procedures. After crossing the AV, traditionally
BAV is performed using an occlusive balloon (20, 23, or
25 × 40mm) under rapid ventricular pacing. In our study,
however, a nonocclusive balloon (12 × 60 or 14 × 60mm;
Osypka AG, Rheinfelden-Herten, Germany) was used for
AVPD (Figure 1). No rapid ventricular pacing was performed
during AVPD. A comparison of balloon sizes in relation to
aortic valve anatomy is provided in Figures 2(a) and 2(b). An
example of pre- and post-AVPD hemodynamic data is shown
in Figure 2(c). Thereafter, the Sapien 3 valve was inserted
and positioned across the AV annulus under fluoroscopy
guidance and deployed under rapid ventricular pacing.
2.3. Procedural Endpoints and Definitions. The primary end-
point was device success. The secondary endpoints were dis-
abling stroke, nondisabling stroke, transient ischemic attack
(TIA), and procedural mortality. Device success, disabling
stroke, nondisabling stroke, TIA, and procedural mortality
were all defined using the VARC2 definitions [6]. Device
success was defined as absence of procedural mortality,
correct positioning of a single prosthetic heart valve, and
intended performance of the implanted prosthetic valve (no
patient-prosthesis mismatch, mean AV gradient < 20mmHg,
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Figure 2: (a) BAVwith a normal “occlusive” valvuloplasty-balloon. (b) AVPDwith a small, “nonocclusive”-balloon. (c)Hemodynamic effects
of AVPD.
or peak velocity < 3m/s and nomoderate or severe prosthetic
valve regurgitation) [6]. Procedural mortality was defined
as all-cause mortality within 30 days or during the index
procedure hospitalization [6].
2.4. Statistical Analysis. Continuous data are presented as
mean± standard deviation, and categorical data are presented
as a number and/or percentages. All analysis was performed
using XLSTAT for Microsoft Excel 2010 (Microsoft Corpora-
tion, Seattle, WA, USA).
3. Results
3.1. Baseline Characteristics. The baseline characteristics of
the study population are shown in Table 1. The mean patient
age was 81 ± 6. Half our patients were women. The mean
logistic EuroSCORE (European System forCardiacOperative
Risk Evaluation) was 13±9.ThemeanAV gradient was 39.9±
15.7mmHg and aortic valve area 0.8 ± 0.2 cm2, indicating
severe aortic stenosis.
3.2. Procedural Data. AVPD was performed using a 12 ×
60mm or 14 × 60mm balloon in 96% of the cases, and in
2 cases (4%) a 12 × 40mm balloon was used. Procedural
data is depicted in Table 2. The mean contrast volume and
fluoroscopy time were 108 ± 35mL and 14 ± 5 minutes,
respectively; mean procedural duration was 60 ± 18minutes.
3.3. Procedural Outcomes. Device success was achieved in
all cases (100%). No periprocedural stroke, disabling stroke,
or TIA occurred. One case (2%) of nondisabling stroke
(transient Wernicke aphasia) occurred more than 24 hours
after TAVR in a patient with chronic atrial fibrillation. Pro-
cedural and 30-day mortality was 0% (Table 3). The patients’
hemodynamics was stable during the procedure in all cases
without the need for additional inotropic medications dur-
ing AVPD or THV implantation. The mean AV gradient
was reduced from 39.9 ± 15.7mmHg to 12.3 ± 4.7mmHg
after THV implantation; these gradients were measured on
pre- and postprocedure echocardiography. No case of aortic
regurgitation grade ≥ 2 occurred (Table 3).
4. Discussion
TAVR as a treatment choice for severe AS is an excellent
option for patients with inoperable or high surgical risk,
but periprocedural stroke remains a concern compared to
surgical aortic valve replacement [1]. BAV is usually per-
formed to ensure the passage of the THV through the
stenotic aortic valve. Another aim of BAV is to improve
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Table 1: Demographic and clinical characteristics of the study
population.
Baseline characteristics
Overall population
(𝑁 = 50)
Age, yrs 80.8 ± 5.9
Female, 𝑛 (%) 25 (50)
BMI, kg/m2 27.3 ± 5.9
Diabetes, 𝑛 (%) 18 (32)
Dyslipidemia, 𝑛 (%) 32 (64)
Hypertension, 𝑛 (%) 45 (90)
Tobacco use, 𝑛 (%) 11 (22)
Coronary artery disease, 𝑛 (%) 35 (70)
Prior MI, 𝑛 (%) 3 (6)
Prior CABG, 𝑛 (%) 3 (6)
Prior PCI, 𝑛 (%) 19 (38)
Prior stroke or TIA, 𝑛 (%) 4 (8)
Peripheral vascular disease, 𝑛 (%) 7 (14)
COPD, 𝑛 (%) 7 (14)
Baseline creatinine, mg/dL 1.1 ± 0.3
Logistic EuroSCORE 2 5.6 ± 5.0
EuroSCORE 13.1 ± 8.8
LVEF, % 52.2 ± 12.5
Maximum aortic gradient, mmHg 65.2 ± 24.0
Mean aortic gradient, mmHg 39.9 ± 15.7
Aortic valve area, cm2 0.8 ± 0.2
Values are 𝑛 (%) or mean ± standard deviation. BMI = body mass index,
MI = myocardial infarction; CABG = coronary artery bypass graft, PCI
= percutaneous coronary intervention, TIA = transient ischemic attack,
COPD= chronic obstructive pulmonary disease, and LVEF = left ventricular
ejection fraction.
Table 2: Procedural data.
Procedural data
Overall population
(𝑁 = 50)
Contrast volume, mL 107.9 ± 35.3
Radiation dose, Gy 32402.5 ± 26989.7
X-ray time, min 13.9 ± 5.2
Length of procedure, min 59.9 ± 17.8
Balloon Size, 𝑛 (%)
12 × 40mm 2 (4)
12 × 60mm 32 (64)
14 × 60mm 16 (32)
Valve Size, 𝑛 (%)
SAPIEN 3 23mm 22 (44)
SAPIEN 3 26mm 19 (38)
SAPIEN 3 29mm 9 (18)
Values are 𝑛 (%) or mean ± SD. F = French.
Table 3: Procedural outcomes.
Procedural outcomes
Complication, 𝑛 (%) Overall population
(𝑁 = 50)
Device success 50 (100)
Aortic regurgitation ≥ grade 2 0 (0)
Mean AV gradient, mmHg 12.3 ± 4.7
Myocardial infarction 1 (2)
Periprocedural stroke 0 (0)
Disabling stroke 0 (0)
Nondisabling stroke 1 (2)
TIA 0 (0)
BARC life threatening/disabling bleeding 0 (0)
BARC major bleeding 4 (8)
BARC minor bleeding 5 (10)
VARC2 major vascular complication 0 (0)
VARC2 minor vascular complication 7 (14)
Permanent pacemaker implant 8 (16)
Acute kidney injury (RIFLE
Classification) 5 (10)
Stage 1 (risk) 2 (4)
Stage 2 (injury) 3 (6)
Stage 3 (failure) 0 (0)
Procedural mortality 0 (0)
Values are 𝑛 (%). AV = aortic valve, TIA = transient ischemic attack, BARC
= bleeding academic research consortium, VARC = valve academic research
consortium, RIFLE = risk, injury, failure, loss of kidney function, and end-
stage kidney disease.
the compliance of the rigid, calcified AV leaflets and to
increase the aortic valve area [7, 8]. With BAV, a sufficient
prosthesis deployment is assured, which is of particular
importance for self-expanding THV exerting less radial
force. Finally, BAV may be used as an additional sizing
modality for prosthesis selection in cases with borderline
or questionable annulus size. The mechanisms underlying
successful BAV are mainly commissural separation and
perhaps more importantly intraleaflet fracturing of calcific
nodules [8–10]. Microembolization of debris is thought to
occur during multiple phases of the procedure, such as
crossing the aortic valve and ascending aorta with different
wires, performing BAV, and positioning of the THV [4, 11].
These microembolizations may account to strokes associated
with TAVR. Multiple studies have identified silent diffuse
embolic strokes on magnetic resonance imaging studies [5].
Moreover, prior studies have demonstrated the advantages of
avoiding BAV in reducing stroke [12, 13]. Reports have also
been published on deleterious outcomes with BAV prior to
TAVR [14]. A currentmeta-analysis suggested a 30-day stroke
rate between 3.2% and 4.2% using the Edwards Sapien valve
[15]. A recently publishedmulticenter trial using the Edwards
Sapien 3 valve observed a 30-day mortality of 2.1% and a rate
of disabling strokes of 0% [16]. The nondisabling stroke rate
was 1% in their transfemoral cohort [16].
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One drawback of BAV is the need for rapid ventricular
pacing to allowhemodynamic arrest of the heart.This ensures
optimal balloon positioning and avoids excessive movements
of the balloon during inflation. These balloon movements
may also contribute to embolization of calcified material
from the stenotic valve [8]. However, rapid left ventricular
pacing carries several risks. First, it may induce ventricular
fibrillation in rare cases [17]. Second, it purposely decreases
cardiac output temporarily with the potential of hemody-
namic instability, especially in patients with aortic stenosis
and hypertrophied left ventricle [18]. Previous studies have
also shown that rapid pacing is associated with smaller post-
BAVAVarea compared to BAV alone [7, 13]. One explanation
of this phenomenonmay be that rapid ventricular pacing pro-
vokes temporary myocardial stunning, thereby decreasing
contractility and flow, resulting in the calculation of a smaller
aortic valve area [18]. In patients with severely reduced LV
function, any additional rapid pacing may be harmful due to
this myocardial stunning. These patients might benefit from
performing AVPD without rapid ventricular pacing instead
of traditional BAV.
In recent reports, operators performdirect TAVRwithout
BAV, also avoiding rapid ventricular pacing [13]. No increase
in adverse outcomes was seen with direct valve implantation
of the Edwards Sapien XT valve [13]. It should be noted,
however, that these were patients with low to moderate
calcification of the AV. Furthermore, it has to be considered
that most of the TAVR valves cannot be withdrawn once
they have entered the body. Thus, failure of crossing the
aortic valve without predilatationmakes the procedure much
more complex. Our prospective analysis shows excellent
procedural success and device success rates using AVPD
without rapid pacing (Table 2). Passage of the THV through
the stenotic AV was achieved on the first attempt in all
patients, even in cases with severely calcified valves. In each
case, single balloon dilation was employed and the rate of
clinical stroke was very low. During the 30 day period, we
observed no disabling stroke, and only one nondisabling
stroke that happened more than 24 h after TAVR in a
patient with chronic atrial fibrillation. Despite the small study
population, this allows us to hypothesize that performing
AVPD with a small balloon is less aggressive in comparison
to BAV and may reduce mortality as well as both the degree
of microembolization and clinical stroke. However, larger
cohorts and corroborative imaging will be needed for a more
definitive conclusion about the impact of AVPD on stroke
and mortality.
5. Study Limitations
This prospective study reflects a single-center experience
usingAVPD in a limited number of patients without a control
group. Since this is not a randomized study, selection bias is
inherent and may have influenced our findings.
6. Conclusion
The use of small balloons for AVPD prior to positioning and
implantation of a transfemoral THV is a safe and feasible
technique. It eliminates the need for rapid pacing without
compromising procedural outcomes. Improvement in the
TAVR procedure with refinement of the device is promising,
but the advancements in procedural techniques described
here are also necessary to improve patient outcomes. Future
randomized trials are required to determine the impact of
AVPD without rapid pacing in comparison to the traditional
BAV and direct THV implantation on hemodynamic and
clinical outcomes, especially on silent and clinical cerebral
ischemia.
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